Cutting-edge clinical trials have solidified the role of combination therapies in advancing treatment outcomes for EGFR-mutant non-small cell lung cancer (NSCLC). Data from the FLAURA2 trial reveal improved overall survival when osimertinib is combined with chemotherapy as a first-line regimen. Subsequent studies indicate ivonescimab, a bispecific antibody, significantly extends progression-free survival (PFS) in patients post-third-generation EGFR-TKI treatment, with regional efficacy differences noted between Western and Chinese cohorts. Further confirmation comes from the ACROSS 2 Phase III trial showing superior PFS with aumolertinib plus chemotherapy. Collectively, these findings advocate for combination protocols to maximize benefits for patients with advanced EGFR-mutated NSCLC.